Sign in
AVIR Stock Price, Chart, Stats & News
Atea Pharmaceuticals, Inc.
Save
348.12M
Market cap
–
Current P/E
–
Forward P/E
AVIR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 3.75% |
ROA | -50.23% |
ROE | -46.34% |
D/E | 0.00x |
Interest coverage ratio | – |
AVIR valuation
P/E | – |
P/S | – |
P/B | 1.45x |
P/CF | -3.03x |
P/FCF | -3.09x |
P/OCF | -3.03x |
PEG | 0.26x |
EV multiple | -2.84x |
About
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.
Similar securities
Based on sector and market capitalization
Report issue